within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX05_Fluorodopa18f;

model Fluorodopa18f
  extends Pharmacolibrary.Drugs.ATC.V.V09IX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>V09IX05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fluorodopa (18F), also known as 6-[18F]fluoro-L-dopa, is a radiolabeled analog of the amino acid L-dopa used primarily as a diagnostic imaging agent in positron emission tomography (PET) for the assessment of presynaptic dopaminergic function, especially in the diagnosis and evaluation of Parkinsonâ€™s disease and related movement disorders. It is not used as a therapeutic drug, but as a diagnostic tool approved in several countries for PET imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers and patients undergoing PET imaging studies.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fluorodopa18f;
